HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
TerminatedNCT03768726

Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolarity type I

This study evaluates the safety of Ziprasidone for people with bipolarity.

Medication studyAges 10–17United States
The study in practice

Understand this study

What is this study about?

This study evaluates the safety of Ziprasidone for people with bipolarity.

Who could participate?

This study is for people with bipolarity. Listed age limits: 10 years to 17 years. Other eligibility criteria apply.

Listed locations
Orange City and 8 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: December 21, 2018
Recruitment status
Terminated
Enrollment listed in the registry
23
Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Sponsor type
Other organization
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
From 10 Years to 17 Years
Official registry ID
NCT03768726
Official title
Show the full official title

26-WEEK OPEN-LABEL EXTENSION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF FLEXIBLE DOSES OF ORAL ZIPRASIDONE IN CHILDREN AND ADOLESCENTS WITH BIPOLAR I DISORDER (MOST RECENT EPISODE MANIC)

Recruitment & locations

Terminated

Orange City · Fayetteville · Smyrna

6 more locations
  • Rochester
  • Cincinnati
  • Oklahoma City
  • Plano
  • The Woodlands
  • Everett

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What is this study about?

This study evaluates the safety of Ziprasidone for people with bipolarity.

Who is behind this study?

The study sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Does this study involve medication?

Yes. The study involves medication, including Ziprasidone and Placebo.

Who can participate?

This study is for people with bipolarity. Listed age limits: 10 years to 17 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies